Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Early-stage or Locally Advanced HER2-positive Breast Cancer”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Not applicableEnded earlyNCT06126003
What this trial is testing

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Who this might be right for
Breast Cancer
BioCorteX Inc 2
Large-scale testing (Phase 3)Study completedNCT03989037
What this trial is testing

SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Shanghai Institute Of Biological Products 580
Large-scale testing (Phase 3)Study completedNCT05415215
What this trial is testing

Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Who this might be right for
Early Breast CancerLocally Advanced Breast CancerInflammatory Breast Cancer
Hoffmann-La Roche 346
Testing effectiveness (Phase 2)Study completedNCT00976989
What this trial is testing

Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 225
Large-scale testing (Phase 3)Study completedNCT03588091
What this trial is testing

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 355
Testing effectiveness (Phase 2)Ended earlyNCT05744375
What this trial is testing

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Spanish Breast Cancer Research Group 2
Testing effectiveness (Phase 2)Study completedNCT02132949
What this trial is testing

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 401
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Early research (Phase 1)Study completedNCT02605915
What this trial is testing

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Who this might be right for
HER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast Cancer
Hoffmann-La Roche 98
Testing effectiveness (Phase 2)Study completedNCT03735966
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Who this might be right for
HER2 Positive Breast Cancer
Henan Cancer Hospital 75
Large-scale testing (Phase 3)Not Yet RecruitingNCT07294534
What this trial is testing

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 817
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287
What this trial is testing

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Who this might be right for
SHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableUnknownNCT03847818
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shandong University 268
Testing effectiveness (Phase 2)UnknownNCT04881929
What this trial is testing

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 30
Testing effectiveness (Phase 2)Looking for participantsNCT04481932
What this trial is testing

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Peking University 104
Large-scale testing (Phase 3)Looking for participantsNCT07196774
What this trial is testing

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Who this might be right for
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 740
Not applicableUnknownNCT03756064
What this trial is testing

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Who this might be right for
Breast CancerNeoplasm, BreastBreast Diseases
Zhejiang Cancer Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)Study completedNCT00545688
What this trial is testing

Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 417
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Load More Results